No votes yet

Pharmacologic Application of Sunitinib Malate in the Management of Gastrointestinal Stromal Tumors

Jessica MacIntyre
CJON 2007, 11(2), 237-241 DOI: 10.1188/07.CJON.237-241

A gastrointestinal stromal tumor (GIST) is a soft tissue sarcoma that can occur anywhere along the gastrointestinal (GI) tract and is the most common noncarcinomatous malignancy of the GI tract. This article will review the pathology of GISTs, the molecular pathology related to c-kit, and disease management and will discuss a new drug approved in the management of GISTs, sunitinib malate. In addition, pharmacologic properties along with nursing considerations related to sunitinib malate will be reviewed.


American Cancer Society. (2006). Detailed guide: Gastrointestinal stromal tumors. Retrieved April 9, 2006, from <a target="_blank" href='http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=81'>http://www.cancer....

Benjamin, R.S., Blanke, C.D., Blay, J.Y., Bonvalot, S., & Eisenberg, B. (2006). Management of gastrointestinal stromal tumors in the imatinib era: Selected case studies. <i>Oncologist</i>, 11, 9-20.

Cawley, M.M., & Benson, L.M. (2005). Current trends in managing oral mucositis. <i>Clinical Journal of Oncology Nursing</i>, 9, 584-592.

Corless, C.L., Fletcher, J.A., & Heinrich, M.C. (2004). Biology of gastrointestinal stromal tumors. <i>Journal of Clinical Oncology</i>, 22, 3813-3825.

D'Amato, G., Steinert, D.M., McAuliffe, J.C., & Trent, J.C. (2005). Update on the biology and therapy of gastrointestinal stromal tumors. <i>Cancer Control</i>, 12, 44-56.

DeMatteo, R.P., Heinrich, M.C., El-Rifai, W.M., & Demetri, G. (2002). Clinical management of gastrointestinal stromal tumors: Before and after STI-571. <i>Human Pathology</i>, 33, 466-477.

Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. <i>New England Journal of Medicine</i>, 347, 472-480.

El-Zohairy, M., Khalil, el-S.A., Fakhr, I., El-Shahawy, M., & Gouda, I. (2005). Gastrointestinal stromal tumors (GIST)'s surgical treatment, NCI experience. <i>Journal of the Egyptian National Cancer Institute</i>, 17, 56-66.

Gold, J.S., & DeMatteo, R.P. (2006). Combined surgery and molecular therapy: The gastrointestinal stomal tumor model. <i>Annals of Surgery</i>, 244, 176-184.

Griffin, J.M., Amand, M.S., & Demetri, G.D. (2005). Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. <i>Clinical Journal of Oncology Nursing</i>, 9, 161-169.

Grimpen, F., Yip, D., McArthur, G., Waring, P., Goldstein, D., Loughrey, M., et al. (2005). Resistance to imatinib, low-grade FDG avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. <i>Lancet Oncology</i>, 6, 724-727.

Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. <i>Clinical Cancer Research</i>, 9, 327-337.

National Cancer Institute. (2003). Common terminology criteria for adverse events v3.0 (CTCAE). Retrieved April 9, 2006, from <a target="_blank" href='http://ctep.cancer.gov'>http://ctep.cancer.gov</a>

National Cancer Institute. (2005). Understanding Cancer Series: Angiogenesis. Retrieved April 9, 2006, from <a target="_blank" href='http://www.cancer.gov/cancertopics/understandingcancer/angiogenesis/slid...

National Comprehensive Cancer Network. (2006). Practice guidelines in oncology v.2.2006. Intra-abdominal sarcomas: Gastrointestinal stromal tumors. Retrieved June 25, 2006, from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf'>http://...

Novartis Oncology. (2003). Gleevec® (imatinib mesylate) [Package insert]. East Hanover, NJ: Author.

Pfizer Oncology. (2006). Sutent® (sunitinib malate) [Package insert]. New York: Author.

Rankin, C., von Mehren, M., Blanke, C., Benjamin, R., Fletcher, C.D., Bramwell, V., et al. (2004). Dose effect of imatinib in patients with metastatic GIST—Phase III Sarcoma Group Study S0033 [Abstract 9005]. <i>Journal of Clinical Oncology</i>, 22(Suppl. 14S), 815.

Sircar, K., Hewlett, B.R., Huizenga, J.D., Chorneyko, K., Berezin, I., & Riddell, R.H. (1999). Interstitial cell of Cajal as precursors of gastrointestinal stromal tumors. <i>American Journal of Surgical Pathology</i>, 23, 377-389.

Stull, D.M. (2003). Targeted therapies for the treatment of leukemia. <i>Seminars in Oncology Nursing</i>, 19, 90-97.

U.S. Food and Drug Administration. (2002). FDA talk paper. Retrieved March 9, 2007, from <a target="_blank" href='http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01134.html'>http://www.fda...

U.S. Library of Medicine. (2007). Genetic mutation and cancer development. Retrieved March 10, 2007, from http://ghr.nlm.nih.gov/handbook/howgeneswork/genesanddivision

von Mehren, M. (2006). New approaches to the management of gastrointestinal stromal tumors. <i>Oncology Special Edition</i>, 9, 97-100.